Register for our free email digests:
Latest From Aldea Pharmaceuticals
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2014.
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Aastrom Biosciences Inc.
- North America
- Parent & Subsidiaries
- Vericel Corp.
- Senior Management
Dominick Colangelo, Pres. & CEO
Gerard Michel, CFO & VP, Corp. Dev.
Ross Tubo, PhD, CSO
Daniel Orlando, COO
David Recker, MD, CMO
- Contact Info
Phone: (617) 252-7999
64 Sidney St.
Cambridge, MA 02139
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.